2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12A.36 Early Experience with the FLAURA2 Regimen in Patients with NSCLC and EGFR Mutations in Latin America

EP.12A.36 Early Experience with the FLAURA2 Regimen in Patients with NSCLC and EGFR Mutations in Latin America

Pdf Summary

This document summarizes an early experience study of the FLAURA2 regimen for treating non-small cell lung cancer (NSCLC) with EGFR mutations in Latin American patients. Osimertinib (Osi), typically given as a first-line treatment for advanced EGFR-mutated NSCLC, led to improved progression-free survival when combined with chemotherapy (CT) in the FLAURA2 trial. Despite benefits, combination treatment resulted in higher adverse events.<br /><br />In this study, 38 patients from five Latin American countries were treated with the FLAURA2 regimen. The patients had a median age of 62, with a majority being male and non-smokers. Many showed central nervous system involvement, and they had a distribution of EGFR mutations: 52.6% del19 and 47.4% L858R. Treatment choices were often prompted by poor prognostic factors, such as CNS disease or a high tumor burden.<br /><br />The results showed that the overall response rate (ORR) to the regimen was 84.3%, with a progression-free survival (PFS) of 7.9 months. However, overall survival data is still immature at a median of 11.3 months. An encouraging percentage (84.2%) of patients maintained a response, though there was a significant rate of G3 toxicity (52.6%), affecting overall patient tolerance and quality of life. One patient died from febrile neutropenia.<br /><br />Conclusively, while the FLAURA2 regimen offers promising initial results with a high ORR, significant adverse effects and increased toxicity highlight the need for longer-term studies to truly assess its impact compared to standard monotherapy, particularly given the burden of EGFR-mutated NSCLC in Latin America. Further research should aim to optimize treatment strategies for these patients, considering their specific clinicobiological characteristics.

Asset Subtitle

Andres Cardona

Meta Tag

Speaker Andres Cardona

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

FLAURA2 regimen

non-small cell lung cancer

NSCLC

EGFR mutations

Osimertinib

chemotherapy

Latin American patients

progression-free survival

adverse events

treatment strategies